Price (delayed)
$0.5625
Market cap
$81.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
$72.8M
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate
There are no recent dividends present for ARDX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.